Practical Nomogram Predicting Apixaban or Rivaroxaban Concentrations from Low-Molecular-Weight Heparin Anti-Xa Values: Special Interest in Acute Ischemic Stroke Patients
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background and Purpose In patients with acute ischemic stroke (AIS) using a direct oral factor-Xa anticoagulant (DOAC) during the last 48 hours, a fixed plasma heparin-calibrated anti-Xa activity (0.5 IU/mL) was proposed as a threshold below which patients could be eligible for thrombolysis and/or thrombectomy. Besides, specific DOAC-calibrated anti-Xa thresholds up to 50 ng/mL have been proposed. However, specific DOAC assays are not widely available contrarily to low-molecularweight heparin (LMWH) anti-Xa activity. We developed and validated a nomogram for predicting apixaban and rivaroxaban concentrations based on LMWH anti-Xa assay. Methods Our prospective study included apixaban (n=325) and rivaroxaban (n=276) patients. On the same sample, we systematically measured specific DOAC concentration and LMWH anti-Xa activity, using STA®-Liquid-Anti-Xa (Stago) and specific DOAC- or LMWH-calibrators, respectively. The nomogram was built using quantifiable values for both assays on the derivation cohorts with a log-linear regression model. Model performances including sensitivity, specificity, and true positive rate for different thresholds were checked on the validation cohorts. Results The models built from the derivation cohorts predicted that values <30 ng/mL and <50 ng/ mL DOAC thresholds corresponded to LMWH-anti-Xa values <0.10 IU/mL and <0.64 IU/mL for apixaban; <0.10 IU/mL and <0.71 IU/mL for rivaroxaban. The model accurately predicted apixaban/ rivaroxaban concentrations in the validation cohort. Conclusions This easy-to-use nomogram, developed with our reagent, allowed accurately predicting DOAC concentrations based on LMWH-anti-Xa results in emergency situations such as AIS when drug-specific assessments are not rapidly available. Using DOAC <50 ng/mL equivalent threshold, instead of the fixed LMWH <0.5 IU/mL one, would allow proposing thrombolysis to more patients.
Abstract
Background and Purpose In patients with acute ischemic stroke (AIS) using a direct oral factor-Xa anticoagulant (DOAC) during the last 48 hours, a fixed plasma heparin-calibrated anti-Xa activity (0.5 IU/mL) was proposed as a threshold below which patients could be eligible for thrombolysis and/or thrombectomy. Besides, specific DOAC-calibrated anti-Xa thresholds up to 50 ng/mL have been proposed. However, specific DOAC assays are not widely available contrarily to low-molecularweight heparin (LMWH) anti-Xa activity. We developed and validated a nomogram for predicting apixaban and rivaroxaban concentrations based on LMWH anti-Xa assay. Methods Our prospective study included apixaban (n=325) and rivaroxaban (n=276) patients. On the same sample, we systematically measured specific DOAC concentration and LMWH anti-Xa activity, using STA®-Liquid-Anti-Xa (Stago) and specific DOAC- or LMWH-calibrators, respectively. The nomogram was built using quantifiable values for both assays on the derivation cohorts with a log-linear regression model. Model performances including sensitivity, specificity, and true positive rate for different thresholds were checked on the validation cohorts. Results The models built from the derivation cohorts predicted that values <30 ng/mL and <50 ng/ mL DOAC thresholds corresponded to LMWH-anti-Xa values <0.10 IU/mL and <0.64 IU/mL for apixaban; <0.10 IU/mL and <0.71 IU/mL for rivaroxaban. The model accurately predicted apixaban/ rivaroxaban concentrations in the validation cohort. Conclusions This easy-to-use nomogram, developed with our reagent, allowed accurately predicting DOAC concentrations based on LMWH-anti-Xa results in emergency situations such as AIS when drug-specific assessments are not rapidly available. Using DOAC <50 ng/mL equivalent threshold, instead of the fixed LMWH <0.5 IU/mL one, would allow proposing thrombolysis to more patients.
참고문헌 (16)
- Meinel TR, "Investigators of the Swiss stroke registry. Prior anticoagulation in patients with ischemic stroke and atrial fibrillation", Ann Neurol, 89, pp.42~53 (2021)
- Berge E, "European Stroke Organisation(ESO)guidelines on intravenous thrombolysis for acute ischaemic stroke", Eur Stroke J, 6, pp.I~LXII (2021)
- Touzé E, "Intravenous thrombolysis for acute ischaemic stroke in patients on direct oral anticoagulants", Eur J Neurol, 25, pp.747~ (2018)
- David J. Seiffge, "Intravenous Thrombolysis in Patients with Stroke Taking Rivaroxaban Using Drug Specific Plasma Levels: Experience with a Standard Operation Procedure in Clinical Practice", 대한뇌졸중영문학회지, 19(3), pp.347~355 (2017), 대한뇌졸중학회
- Seiffge DJ, "Intravenous thrombolysis in patients taking direct oral anticoagulants(ESO IVT guidelines comment)", Eur Stroke J, 6, pp.445~446 (2021)
- Douxfils J, "2021 Update of the International Council for Standardization in Haematology Recommendations for laboratory measurement of direct oral anticoagulants", Thromb Haemost, 121, pp.1008~1020 (2021)
- Ebner M, "Limitations of specific coagulation tests for direct oral anticoagulants : a critical analysis", J Am Heart Assoc, 7, pp.e009807~ (2018)
- Beyer J, "Evaluation of a heparin-calibrated antifactor Xa assay for measuring the anticoagulant effect of oral direct Xa inhibitors", Clin Appl Thromb Hemost, 22, pp.423~428 (2016)
- Maier CL, "Using an old test for new tricks : measuring direct oral anti-Xa drug levels by conventional heparin-calibrated anti-Xa assay", Am J Hematol, 94, pp.E132~E134 (2019)
- Boissier E, "Heparin anti-Xa activity, a readily available unique test to quantify apixaban, rivaroxaban, fondaparinux, and danaparoid levels", Anesth Analg, 132, pp.707~716 (2021)
- Willekens G, "A universal anti-Xa assay for rivaroxaban, apixaban, and edoxaban measurements: method validation, diagnostic accuracy and external validation", Br J Haematol, 193, pp.1203~1212 (2021)
- Meihandoest T, "Accuracy of a single, heparin-calibrated anti-Xa assay for the measurement of rivaroxaban, apixaban, and edoxaban drug concentrations: a prospective cross-sectional study", Front Cardiovasc Med, 9, pp.817826~ (2022)
- Mithoowani S, "Low molecular weight heparin anti-Xa assays can identify patients with clinically important apixaban and rivaroxaban drug levels", Thromb Res, 215, pp.1~4 (2022)
- von Horn H, "Using a low-molecular weight heparin-calibrated antifactor Xa assay to assess the concentration of apixaban and rivaroxaban", Int J Lab Hematol, 44, pp.163~167 (2022)
- Shahjouei S, "Safety of intravenous thrombolysis among patients taking direct oral anticoagulants : a systematic review and meta-analysis", Stroke, 51, pp.533~541 (2020)
- Lessire S, "Estimation of rivaroxaban plasma concentrations in the perioperative setting in patients with or without heparin bridging", Clin Appl Thromb Hemost, 24, pp.129~138 (2018)